UBS Initiates Coverage on Ensysce Biosciences With Buy Rating
UBS has initiated research coverage on Ensysce Biosciences with a Buy rating and a price target of $2.00.
Stocks · News reference
Ensysce Biosciences announced its financial results for the third quarter ended September 30, 2026, highlighting the impact of its recent Cy Biopharma acquisition and progress in its clinical pipeline.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
UBS has initiated research coverage on Ensysce Biosciences with a Buy rating and a price target of $2.00.
Filed: 2026-11-12 AccNo: 0001493152-26-051414 Size: 284 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Analysts initiated coverage on KE, MBX, ENSC, DORM and AGLT, issuing mostly Buy/positive ratings with new price targets.
Ensysce Biosciences announced that CEO Lynn Kirkpatrick will transition to the role of Chief Operating Officer, with President James Morrisson set to assume the CEO position following the company's annual meeting on December 14, 2026.
Ensysce Biosciences announced an expansion of its global investor and strategic outreach efforts at the Family Office Summit in Dubai.
Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Ensysce Biosciences (NASDAQ:ENSC) with a Overweight rating and announces Price Target of $2.